flutamide has been researched along with Metabolic Syndrome in 2 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 7.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 3.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, HR | 1 |
| Abraham, DJ | 1 |
| Kupreeva, M | 1 |
| Diane, A | 1 |
| Lehner, R | 1 |
| Watts, R | 1 |
| Ghosh, M | 1 |
| Proctor, S | 1 |
| Vine, D | 1 |
2 other studies available for flutamide and Metabolic Syndrome
| Article | Year |
|---|---|
Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.
Topics: Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Chenodeoxycholic Acid; DNA-Binding Prot | 2006 |
Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
Topics: Androgen Antagonists; Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Blood G | 2019 |